The Chinese government said on Tuesday it will scrap long-standing state price controls on most medicines, effective June 1, as part of market-oriented reforms.The government will no longer impose upper limits on retail prices for drugs, government agencies including the National Development and Reform Commission.
“The reform of drug prices needs to… fully utilise the resource allocation role of the market,” the statement said.
Price controls will be relaxed over drugs covered by medical insurance, blood products, immunisations, anti-AIDS and birth-control medicines, the statement said.
“The reform of drug prices needs to… fully utilise the resource allocation role of the market,” the statement said.
Price controls will be relaxed over drugs covered by medical insurance, blood products, immunisations, anti-AIDS and birth-control medicines, the statement said.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI